Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00185874 · ClinicalTrials.gov registry record · Phase 1
Phase I Intratumoral Dendritic Cell Immunotherapy in Thermally Ablated Liver Metastases
A Phase 1 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00185874: Clinical Trial Phase 1 study, sponsored by Stanford University.
NCT00185874 is a Phase 1 study that was terminated before completion, run by Stanford University. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00185874, a Phase 1 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
Up to twenty-two patients will be enrolled in this study to receive autologous dendritic cells (DCs) administered intratumorally into liver metastases following radiofrequency thermal ablation of those lesions. Patients will receive two vaccinations of DCs at monthly intervals. A dose escalation study of DCs will be included in this study in an attempt to define the maximum tolerated dose of administered DCs.
Interventions
- BIOLOGICAL autologous dendritic cells
- BIOLOGICAL Intratumoral Dendritic Cell Immunotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2004-01 |
| Est. Completion | 2007-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00185874
The ClinicalTrials.gov registry entry for NCT00185874 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which autologous dendritic cells is the first listed.
NCT00185874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00185874 about?
NCT00185874 is a clinical study titled "Phase I Intratumoral Dendritic Cell Immunotherapy in Thermally Ablated Liver Metastases". Up to twenty-two patients will be enrolled in this study to receive autologous dendritic cells (DCs) administered intratumorally into liver metastases following radiofrequency thermal ablation of those lesions. Patients will receive two vaccinations of DCs at monthly intervals. A dose escalation stu...
What is the current status of trial NCT00185874?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2004-01. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00185874?
The interventions under investigation include: autologous dendritic cells (BIOLOGICAL), Intratumoral Dendritic Cell Immunotherapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00185874?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.